BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 22132100)

  • 1. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
    Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
    PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
    Gregson J; Kaleebu P; Marconi VC; van Vuuren C; Ndembi N; Hamers RL; Kanki P; Hoffmann CJ; Lockman S; Pillay D; de Oliveira T; Clumeck N; Hunt G; Kerschberger B; Shafer RW; Yang C; Raizes E; Kantor R; Gupta RK
    Lancet Infect Dis; 2017 Mar; 17(3):296-304. PubMed ID: 27914856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.
    TenoRes Study Group
    Lancet Infect Dis; 2016 May; 16(5):565-575. PubMed ID: 26831472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
    Manasa J; Lessells RJ; Skingsley A; Naidu KK; Newell ML; McGrath N; de Oliveira T;
    PLoS One; 2013; 8(8):e72152. PubMed ID: 23991055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
    Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
    Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
    J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian network analyses of resistance pathways against efavirenz and nevirapine.
    Deforche K; Camacho RJ; Grossman Z; Soares MA; Van Laethem K; Katzenstein DA; Harrigan PR; Kantor R; Shafer R; Vandamme AM;
    AIDS; 2008 Oct; 22(16):2107-15. PubMed ID: 18832874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
    Wallis CL; Papathanasopolous MA; Fox M; Conradie F; Ive P; Orrell C; Zeinecker J; Sanne I; Wood R; McIntyre J; Stevens W;
    Antivir Ther; 2012; 17(2):313-20. PubMed ID: 22293461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
    BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
    Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
    Tang MW; Rhee SY; Bertagnolio S; Ford N; Holmes S; Sigaloff KC; Hamers RL; de Wit TF; Fleury HJ; Kanki PJ; Ruxrungtham K; Hawkins CA; Wallis CL; Stevens W; van Zyl GU; Manosuthi W; Hosseinipour MC; Ngo-Giang-Huong N; Belec L; Peeters M; Aghokeng A; Bunupuradah T; Burda S; Cane P; Cappelli G; Charpentier C; Dagnra AY; Deshpande AK; El-Katib Z; Eshleman SH; Fokam J; Gody JC; Katzenstein D; Koyalta DD; Kumwenda JJ; Lallemant M; Lynen L; Marconi VC; Margot NA; Moussa S; Ndung'u T; Nyambi PN; Orrell C; Schapiro JM; Schuurman R; Sirivichayakul S; Smith D; Zolfo M; Jordan MR; Shafer RW
    J Infect Dis; 2013 Jun; 207 Suppl 2(Suppl 2):S70-7. PubMed ID: 23687292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Musengimana G; Tuyishime E; Kiromera A; Malamba SS; Mulindabigwi A; Habimana MR; Baribwira C; Ribakare M; Habimana SD; DeVos J; Mwesigwa RCN; Kayirangwa E; Semuhore JM; Rwibasira GN; Suthar AB; Remera E
    Antivir Ther; 2022 Jun; 27(3):13596535221102690. PubMed ID: 35593031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
    Bulteel N; Bansi-Matharu L; Churchill D; Dunn D; Bibby D; Hill T; Sabin C; Nelson M; ;
    J Infect; 2014 Jan; 68(1):77-84. PubMed ID: 24055802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
    Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
    PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.